Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development

Journal of Clinical Pharmacology

Volumn 43, Issue 9, 2003, Pages 1008-1014

  Smith, Judith A ^a   Newman, Robert A ^a   Hausheer, Frederick H ^b   Madden, Timothy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BioNumerik Pharmaceuticals Inc   (United States)

Author keywords

Anticancer agent; Camptothecin; Karenitecin; Metabolism; Oncology; Pharmacodynamics; Pharmacokinetics; Plasma; Protein binding; Urine

Indexed keywords

ALBUMIN; ALPHA ACIDIC GLYCOPROTEIN; BUFFER; BUFURALOL; CAMPTOTHECIN DERIVATIVE; CELLULOSE; CYTOCHROME P450 2C8; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DICLOFENAC; ENZYME INHIBITOR; GLYCOPROTEIN; KARENITECIN; KETOCONAZOLE; MITOXANTRONE; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; QUINIDINE; SALICYLIC ACID; SULFAPHENAZOLE; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL MEMBRANE; DIALYSIS; DRUG DEVELOPMENT; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME SUBSTRATE; HUMAN; IN VITRO STUDY; LIPOPHILICITY; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PLASMA; PROTEIN BLOOD LEVEL;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; ISOENZYMES; OROSOMUCOID; PROTEIN BINDING; SERUM ALBUMIN;

EID: 0043014526     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003255921     Document Type: Article

References (20)

1. Takimoto CH, Kieffer LV, Arbuck SG: DNA topoisomerase I inhibitors. Cancer Chemother Biol Response Modif 1997;17:80-113.
2. Takimoto CH, Dahut W, Marino MT, Nakashima H, Liang MD, Harold H, et al: Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 1997;15(4):1492-1501.
3. Yao S, Murali D, Seetharmulu P, Haridas K, Petluru P, Reddy DG, et al: Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I. Cancer Res 1998;58:3782-3786.
4. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85(4):271-291.
5. Dancey J, Eisenhauer EA: Current perspectives on camptothecins in cancer treatment. Br J Cancer 1996;74(3):327-338.
6. Wisemen LR, Markham A: Irinotecan: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996;52(4):606-623.
7. Rothenberg ML, Eckardt JR, Kuhn JG, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14(4):1128-1135.
8. Conti JA, Kemeny NE, Saltz LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14(3):709-715.
9. Hausheer FH, Haridas K, Zhao M, Murali D, Seetharamulu P, Yao S, et al: Karenitecins: a novel class of orally active highly lipophilic topoisomerase I inhibitors. Proc Am Assoc Cancer Res 1997;39:420.
10. Smith JA, Hausheer F, Newman R, Madden TL: Assay development and interim pharmacokinetic analysis of karenitecin, a novel highly lipophilic camptothecin derivative [abstract]. Pharmacotherapy 1999;19(10):1192.
11. Crespi CL, Chang TKH, Waxman DJ: High-performance liquid chromatographic analysis of CYP2C8-catalyzed paclitaxel 6α-hydroxylation, in: Phillips IR, Shephard EA (eds.), Methods in Molecular Biology: Vol. 107. Cytochrome P450 Protocols. Totowa, NJ: Humana Press, 1999;123-127.
12. Crespi CL, Chang TKH, Waxman DJ: Determination of CYP2C9-catalyzed diclofenac 4′-hydroxylation by high performance liquid chromatography, in: Phillips IR, Shephard EA (eds.), Methods in Molecular Biology: Vol. 107. Cytochrome P450 Protocols. Totowa, NJ: Humana Press, 1999;129-133.
13. Crespi CL, Chang TKH, Waxman DJ: CYP2D6-dependent bufuralol 1′-hydroxylation assayed by reverse-phase ion-pair high-performance liquid chromatography with fluorescence detection, in: Phillips IR, Shephard EA (eds.), Methods in Molecular Biology: Vol. 107. Cytochrome P450 Protocols. Totowa, NJ: Humana Press, 1999;141-145.
14. Sanwald P, Blankson EA, Dulery BD, Schoun J, Huebert ND, Dow J: Isocratic high-performance liquid chromatographic method for the separation of testosterone metabolites. J Chromato B 1995;672:207-215.
15. Smith JA, Hausheer F, Newman RA, Madden T: Development of a high-performance liquid chromatographic method to determine the concentration of karenitecin, a novel highly lipophilic camptothecin derivative, in human plasma and urine. J Chromato B 2001;759:117-127.
16. Burke TG, Mi Z: The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 1994;37(1):40-46.
17. Bon D, Curran DP, Kruszewski S, et al: The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 2000;43(21):3970-3980.
18. Kremer JMH, Wilting J, Janssen LH: Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988;40(1):1-39.
19. Gambacorti-Passerini C, Barni R, le Coutre P, Zuccheti M, et al: Role of α 1 acid glycoprotein in the in vivo resistance of human bcr-Abl+ leukemia cells to the Abl inhibitor STI571. J Natl Cancer Inst 2000;92(20):1641-1650.
20. Takimoto CH, Arbuck SG: Camptothecins, in: Chabner BA, Lango DL (eds.), Cancer Chemotherapy and Biotherapy: Principles and Practice. 2nd ed. Philadelphia: Lippincott, 1996